CopiOs Posterolateral Fusion Procedure

NCT ID: NCT01123850

Last Updated: 2015-05-27

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-06-30
• Study Completion Date: 2012-10-31

Brief Summary

To compare radiographic data collection from patients undergoing instrumented PLF with CopiOs(R) BVF or instrumented PLF with autologous bone and to assess overall clinical outcomes. Patients will serve as self controls.

Detailed Description

This is a prospective, counter-balanced study involving 85 subjects at up to 8 investigative centers. Each subject will be an appropriate candidate for an instrumented PLF and will meet the inclusion and exclusion criteria. All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study. Data will be collected pre-operatively, operatively and post-operatively at six and twelve months.

The study objectives include: Radiographic success of CopiOs is non-inferior to autograft with clear evidence of bridging bone. Radiographic analysis will be used to show that CopiOs works as well as autograft when comparing the rate of fusion at 6 and 12 months. The CT scan (12 month) will show that CopiOs works as well as autograft when comparing the fusion mass between the transverse processes. Additionally, clinical success will be determined by an improvement of 15 percentage points using the Oswestry Disability Index and maintenance or improvement in the motor and sensory components of the neurological assessment from preoperative to postoperative. Since patients serve as self-controls there will be no clinical success comparisons between the groups. Rather, clinical success will be measured on overall improvement based on patient outcomes.

Conditions

Spondylolisthesis; Stenosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single ARM - Copios Bone Filler

All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.

Group Type: ACTIVE_COMPARATOR

Copios

Intervention Type: DEVICE

Bone Void Filler

Interventions

Copios

Bone Void Filler

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient must be skeletally mature; between the ages of 21 and 75
• Patients having degenerative spondylolisthesis, stenosis with instability, or degenerative disc disease as diagnosed by radicular signs and/or imaging studies
• Patients will be medically indicated for a single-level, instrumented PLF between L2 and S1 per their surgeon
• Patient must be willing and able to comply with study requirements, including all necessary study related paperwork and follow-up visits

Exclusion Criteria

• Use of iliac crest bone graft;
• Any previous lumbar spinal surgeries at indicated level;
• Any medical or physical condition that would preclude the potential benefit of spinal surgery;
• Use of a dynamic stabilization systems;
• Sites where stresses on void will exceed the load strength of fixation of hardware;
• Segmental defects;
• Significantly impaired vascularity proximal to the surgical site;
• Sites in direct contact with articular space;
• Soft tissue deficit not allowing closure;
• Active systemic or local infection;
• Severe degenerative bone disease;
• Patients with osteoporosis who are actively under treatment;
• Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI>40 kg/m2);
• Active malignancy;
• Patients with a history of multiple allergies;
• Patients with known allergies to bovine collagen;
• Hypercalcemia;
• Pregnancy;
• Mental illness;
• Alcohol or drug abuse;
• Incarceration.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zimmer Biomet

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Florida Hospital

Orlando, Florida, United States

Neurological Surgery of Southern Illinois

Belleville, Illinois, United States

Indiana Orthopedic Center

Indianapolis, Indiana, United States

Las Cruces Orthopaedic Associates

Las Cruces, New Mexico, United States

Upstate Bone and Joint Center

East Syracuse, New York, United States

Scott and White Healthcare

Temple, Texas, United States

Countries

United States

Other Identifiers

2008-001

Identifier Type: -

Identifier Source: org_study_id